Sublingual administration of bacteria-expressed influenza virus hemagglutinin 1 (HA1) induces protection against infection with 2009 pandemic H1N1 influenza virus

Journal of Microbiology

Volumn 51, Issue 1, 2013, Pages 130-135

  Shim, Byoung Shik ^a   Choi, Jung ah ^a   Song, Ho Hyun ^a   Park, Sung Moo ^a,b   Cheon, In Su ^a,b   Jang, Ji Eun ^a   Woo, Sun Je ^a,b   Cho, Chung Hwan ^a,b   Song, Min Suk ^c   Kim, Hyemi ^d   Song, Kyung Joo ^d   Lee, Jae Myun ^d   Kim, Suhng Wook ^e   Song, Dae Sub ^f   Choi, Young Ki ^c   Kim, Jae Ouk ^a   Nguyen, Huan Huu ^a   Kim, Dong Wook ^g   Bahk, Young Yil ^h   Yun, Cheol Heui ^b   Song, Man Ki ^a   more..

^a International Vaccine Institute   (South Korea)

^b Seoul National University   (South Korea)

^c Chungbuk National University College of Medicine   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e Korea University   (South Korea)

^f Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^g Hanyang University   (South Korea)

^h Konkuk University   (South Korea)

Author keywords

Hemagglutinin; mucosal immune response; non glycosylation; pandemic; sublingual

Indexed keywords

CHOLERA TOXIN; H1N1 VIRUS HEMAGGLUTININ; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; VIRUS ANTIBODY;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BLOOD; DISEASE MODEL; ENZYME LINKED IMMUNOSPOT ASSAY; GENETICS; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFLUENZA VIRUS A H1N1; LUNG; MONONUCLEAR CELL; MOUSE; MUCOSAL IMMUNITY; ORTHOMYXOVIRUS INFECTION; SERUM; SUBLINGUAL DRUG ADMINISTRATION; VIROLOGY; VIRUS LOAD;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, SUBLINGUAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHOLERA TOXIN; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSPOT ASSAY; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNITY, MUCOSAL; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; LEUKOCYTES, MONONUCLEAR; LUNG; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; SERUM; VACCINES, SYNTHETIC; VIRAL LOAD;

EID: 84874562182     PISSN: 12258873     EISSN: 19763794     Source Type: Journal    
DOI: 10.1007/s12275-013-2399-z     Document Type: Article

References (30)

1. Agostinis, F., Tellarini, L., Canonica, G. W., Falagiani, P., and Passalacqua, G. 2005. Safety of sublingual immunotherapy with a monomeric allergoid in very young children. Allergy60, 133.
2. Aguilar-Yanez, J. M., Portillo-Lara, R., Mendoza-Ochoa, G. I., Garcia-Echauri, S. A., Lopez-Pacheco, F., Bulnes-Abundis, D., Salgado-Gallegos, J., Lara-Mayorga, I. M., Webb-Vargas, Y., Leon-Angel, F. O., andet al. 2010. An influenza A/H1N1/2009 hemagglutinin vaccine produced in Escherichia coli. PLoS ONE5, e11694.
3. Ahmed, R., Oldstone, M. B., and Palese, P. 2007. Protective immunity and susceptibility to infectious diseases: Lessons from the 1918 influenza pandemic. Nat. Immunol. 8, 1188-1193.
4. Akdis, M. 2008. Immunologic responses to sublingual allergen immunotherapy. Clin. Allergy Immunol. 21, 71-86.
5. Armstrong, M. E., Lavelle, E. C., Loscher, C. E., Lynch, M. A., and Mills, K. H. 2005. Proinflammatory responses in the murine brain after intranasal delivery of cholera toxin: Implications for the use of ab toxins as adjuvants in intranasal vaccines. J. Infect. Dis. 192, 1628-1633.
6. Asahi-Ozaki, Y., Itamura, S., Ichinohe, T., Strong, P., Tamura, S., Takahashi, H., Sawa, H., Moriyama, M., Tashiro, M., and Sata, T. 2006. Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection. Microbes Infect. 8, 2706-2714.
7. Berhanu, A., Wilson, R. L., Kirkwood-Watts, D. L., King, D. S., Warren, T. K., Lund, S. A., Brown, L. L., Krupkin, A. K., VanderMay, E., and Weimers, W. 2008. Vaccination of balb/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge. J. Virol. 82, 3517-3529.
8. Brandtzaeg, P. and Pabst, R. 2004. Let's go mucosal: Communication on slippery ground. Trends Immunol. 25, 570-577.
9. Cuburu, N., Kweon, M. N., Song, J. H., Hervouet, C., Luci, C., Sun, J. B., Hofman, P., Holmgren, J., Anjuere, F., and Czerkinsky, C. 2007. Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine25, 8598-8610.
10. Dormitzer, P. R., Galli, G., Castellino, F., Golding, H., Khurana, S., Del Giudice, G., and Rappuoli, R. 2011. Influenza vaccine immunology. Immunol. Rev. 239, 167-177.
11. Fujihashi, K., Koga, T., van Ginkel, F. W., Hagiwara, Y., and McGhee, J. R. 2002. A dilemma for mucosal vaccination: Efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine20, 2431-2438.
12. Hai, R., Garcia-Sastre, A., Swayne, D. E., and Palese, P. 2011. A reassortment-incompetent live attenuated influenza virus vaccine for protection against pandemic virus strains. J. Virol. 84, 6832-6843.
13. Hebert, D. N., Zhang, J. X., Chen, W., Foellmer, B., and Helenius, A. 1997. The number and location of glycans on influenza hemagglutinin determine folding and association with calnexin and calreticulin. J. Cell Biol. 139, 613-623.
14. Holmgren, J. and Czerkinsky, C. 2005. Mucosal immunity and vaccines. Nat. Med. 11, S45-53.
15. Igarashi, M., Ito, K., Yoshida, R., Tomabechi, D., Kida, H., and Takada, A. 2010. Predicting the antigenic structure of the pandemic (H1N1) 2009 influenza virus hemagglutinin. PLoS ONE5, e8553.
16. Khan, K., Arino, J., Hu, W., Raposo, P., Sears, J., Calderon, F., Heidebrecht, C., Macdonald, M., Liauw, J., Chan, A., andet al. 2009. Spread of a novel influenza a (H1N1) virus via global airline transportation. N. Engl. J. Med. 361, 212-214.
17. Kim, J. K., Seiler, P., Forrest, H. L., Khalenkov, A. M., Franks, J., Kumar, M., Karesh, W. B., Gilbert, M., Sodnomdarjaa, R., Douangngeun, B., andet al. 2008. Pathogenicity and vaccine efficacy of different clades of Asian H5N1 avian influenza a viruses in domestic ducks. J. Virol. 82, 11374-11382.
18. Liew, F. Y., Russell, S. M., Appleyard, G., Brand, C. M., and Beale, J. 1984. Cross protection in mice infected with influenza a virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity. Eur. J. Immunol. 14, 350-356.
19. Meng, S., Liu, Z., Xu, L., Li, L., Mei, S., Bao, L., Deng, W., Lei, R., and Xie, L. 2011. Intranasal immunization with recombinant HA and mast cell activator C48/80 elicits protective immunity against 2009 pandemic H1N1 influenza in mice. PLoS ONE6, e19863.
20. Reed, L. J. and Muench, H. 1938. A simple method of estimating fifty percent endpoints. Am. J. Epidemiol. 27, 493-497.
21. Reisinger, K. S., Block, S. L., Izu, A., Groth, N., and Holmes, S. J. 2009. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: Comparison of safety, reactogenicity, and immunogenicity. J. Infect. Dis. 200, 849-857.
22. Renegar, K. and Small Jr, P. 1991. Immunoglobulin a mediation of murine nasal anti-influenza virus immunity. J. Virol. 65, 2146-2148.
23. Shih, A. C. C., Hsiao, T. C., Ho, M. S., and Li, W. H. 2007. Simultaneous amino acid substitutions at antigenic sites drive influenza a hemagglutinin evolution. Proc. Natl. Acad. Sci. USA104, 6283.
24. Skehel, J. J. and Wiley, D. C. 2000. Receptor binding and membrane fusion in virus entry: The influenza hemagglutinin. Annu. Rev. Biochem. 69, 531-569.
25. Song, L., Nakaar, V., Kavita, U., Price, A., Huleatt, J., Tang, J., Jacobs, A., Liu, G., Huang, Y., Desai, P., andet al. 2008a. Efficacious recombinant influenza vaccines produced by high yield bacterial expression: A solution to global pandemic and seasonal needs. PLoS ONE3, e2257.
26. Song, J. H., Nguyen, H. H., Cuburu, N., Horimoto, T., Ko, S. Y., Park, S. H., Czerkinsky, C., and Kweon, M. N. 2008b. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc. Natl. Acad. Sci. USA105, 1644-1649.
27. Song, M. S., Oh, T. K., Pascua, P. N., Moon, H. J., Lee, J. H., Baek, Y. H., Woo, K. J., Yoon, Y., Sung, M. H., Poo, H., andet al. 2009. Investigation of the biological indicator for vaccine efficacy against highly pathogenic avian influenza (HPAI) H5N1 virus challenge in mice and ferrets. Vaccine27, 3145-3152.
28. Stevens, J., Corper, A. L., Basler, C. F., Taubenberger, J. K., Palese, P., and Wilson, I. A. 2004. Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science303, 1866-1870.
29. Verhoeyen, M., Fang, R., Jou, W. M., Devos, R., Huylebroeck, D., Saman, E., and Fiers, W. 1980. Antigenic drift between the haemagglutinin of the hong kong influenza strains A/Aichi/2/68 and A/Victoria/3/75. Nature286, 771-776.
30. Yuki, Y. and Kiyono, H. 2009. Mucosal vaccines: Novel advances in technology and delivery. Expert Rev. Vaccines8, 1083-1097.